cc-11050
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01300208)
Timeline
Indications
Mechanism of action
HIVEP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cc-11050
- cc-11050
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04139226 | Phase 1 | Aug 28, 2019 | Celgene |
| NCT03807362 | Phase 2 | Jan 7, 2018 | The Leprosy Mission Nepal |
| NCT02968927 | Phase 2 | Nov 1, 2016 | Aurum Institute |
| NCT01300208 | Phase 2 | Oct 1, 2010 | Celgene |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 2 | 2 | 2 | 2010 |
| Aurum Institute | Academic/Hospital | 1 | 1 | 1 | 2016 |
| The Leprosy Mission Nepal | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1